Occam Places Two Board Members at George Church Biotech
In August 2025, Occam Global recruited Doug Williams, PhD, and Adam Craig, MD, PhD, to the eGenesis board.
Douglas Williams, PhD, is a senior R&D leader with over 30 years of experience gained at Biogen, ZymoGenetics, Amgen, and Seagen, and has contributed to such notable therapies as Enbrel®, Tecfidera®, and Spinraza®. Williams was President of R&D at Sana Biotechnology and founding CEO of Codiak Biosciences. He now chairs Climb Bio and serves on the board of CAMP4 Therapeutics.
Adam Craig, MD, PhD, brings 25+ years of drug development and commercialization expertise in oncology, hematology, and rare diseases. As CEO of CTI BioPharma, he led Vonjo® to approval and commercialization and then sold that company to Swedish Orphan Biovitrum AB (Sobi) in 2023 for ~$1.7 billion. He now serves as Executive Chairman of X4 Pharmaceuticals and as a member of Stratus Therapeutics’ board.
About eGenesis
eGenesis isa George Church company pioneering a genome engineering-based approach to develop safe and effective transplantable organs, ultimately ending the global organ shortage. In the last year, the company has successfully completed two porcine-human kidney transplants and is utilizing funds from a recently closed $191M Series D round to advance programs in the heart, liver, and kidney to the clinic. Investors include Lux Capital, ARCH Ventures, Khosla Ventures, Farallon Capital Management, Leaps by Bayer, Polaris Partners, Catalio Capital Management, and Osage University Partners.
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.